Duke Genomics Institute Readies Prospective Trial to Test PGx Model for Chemotherapy | GenomeWeb
CHICAGO (GenomeWeb News) — Duke University’s Institute for Genome Sciences and Policy this fall will launch a prospective Phase IIb trial to learn whether a pharmacogenomic-based prognostic model can be used to change the way oncologists treat an early form of non-small cell lung cancer.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.